2012-10-10 01:19:32 - New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research

Global Market Direct's pharmaceuticals report, "Txcell SA - Product Pipeline Review - 2012" provides data on the Txcell SA's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Txcell SA's corporate website, SEC filings, investor presentations and featured press releases, both from Txcell SA and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

* Txcell SA - Brief Txcell SA overview including business description, key information and facts, and its locations and subsidiaries.
* Review of current pipeline of Txcell SA human therapeutic division.
* Overview of pipeline therapeutics

across various therapy areas.
* Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
* Product profiles for late stage and clinical stage products of Txcell SA with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
* Recent updates of the Txcell SA's pipeline in the last quarter.
* Key discontinued and dormant projects.
* Latest news and deals relating to the products.


Full Report Details at
- www.fastmr.com/prod/468614_txcell_sa_product_pipeline_review_201 ..


Reasons to buy

* Evaluate Txcell SA's strategic position with total access to detailed information on its product pipeline.
* Assess the growth potential of Txcell SA in its therapy areas of focus.
* Identify new drug targets and therapeutic classes in the Txcell SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
* Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
* Exploit collaboration and partnership opportunities with Txcell SA.
* Avoid Intellectual Property Rights related issues.
* Explore the dormant and discontinued projects of Txcell SA and identify potential opportunities in those areas.

Report Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
TxCell SA Snapshot
TxCell SA Overview
Key Information
Key Facts
TxCell SA - Research and Development Overview
Key Therapeutic Areas
TxCell SA - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
TxCell SA - Pipeline Products Glance
TxCell SA Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
TxCell SA - Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
TxCell SA - Drug Profiles
Drug For Asthma
Product Description
Mechanism of Action
R&D Progress
Drug For HSP
Product Description
Mechanism of Action
R&D Progress
Drug For Type I Diabetes
Product Description
Mechanism of Action
R&D Progress
OvaSave
Product Description
Mechanism of Action
R&D Progress
TX-MSD
Product Description
Mechanism of Action
R&D Progress
TX-RAD
Product Description
Mechanism of Action
R&D Progress
UC1-TX
Product Description
Mechanism of Action
R&D Progress
TxCell SA - Pipeline Products by Route of Administration
TxCell SA - Recent Pipeline Updates
TxCell SA - Locations And Subsidiaries
Head Office
Financial Deals Landscape
TxCell SA, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
TxCell Secures $15.79 Million In Second Round Of Financing
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
TxCell SA, Key Information
TxCell SA, Key Facts
TxCell SA - Pipeline by Indication, 2012
TxCell SA - Pipeline by Stage of Development, 2012
TxCell SA - Monotherapy Products in Pipeline, 2012
TxCell SA - Phase II, 2012
TxCell SA - Phase I, 2012
TxCell SA - Pre-Clinical, 2012
TxCell SA - Pipeline By Route of Administration, 2012
TxCell SA - Recent Pipeline Updates, 2012
TxCell Secures $15.79 Million In Second Round Of Financing

List of Figures
TxCell SA - Pipeline by Indication, 2012
TxCell SA - Pipeline by Stage of Development, 2012
TxCell SA - Monotherapy Products in Pipeline, 2012
TxCell SA - Pipeline By Route of Administration, 2012

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.